

04 Sep 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: new data for Factor XIa inhibitors; Farxiga in heart failure; Lumakras succeeds in lung cancer; MSD's India head on company plans; and BeiGene's confidence in IO/IO combinations.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 2 September 2022, including: new data for Factor XIa inhibitors; Farxiga in heart failure; Lumakras succeeds in lung cancer; [MSD's India head on company plans](#); and [BeiGene, Ltd.](#)'s confidence in IO/IO combinations.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Confidence In Factor XIa Inhibition Wavers After Bristol/Janssen And Bayer Data](#)" - Scrip, 29 Aug, 2022.)

(Also see "[Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure](#)" - Scrip, 29 Aug, 2022.)

(Also see "[Amgen's Lumakras Succeeds In Confirmatory Lung Cancer Trial](#)" - Scrip, 30 Aug, 2022.)

(Also see "[MSD India Chief On The Now, Next For Januvia, Gardasil And Keytruda's Ascent](#)" - Scrip, 29 Aug, 2022.)

SCRIP

CITELINE COMMERCIAL

(Also see "[BeiGene Is Keeping The Faith In IO/IO Combinations](#)" - Scrip, 31 Aug, 2022.)

[Click here to explore this interactive content online](#) ✨